-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026- HAYWARD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDA ...

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE)What: Securities fraud class action lawsuit filedClass Period: September 24, 2025, and October 31, 2025Deadline to Seek Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s Huntington’s disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.c ...

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging material misstatements regarding the company's Huntington's disease gene therapy drug [1]. Group 1: Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1]. - The class period for the lawsuit is defined as September 24, 2025, to October 31, 2025, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. - The allegations include misleading statements about the Phase I/II clinical trials of uniQure's leading drug candidate, AMT-130, and the timeline for its Biologics License Application (BLA) submission to the FDA [1]. Group 2: Allegations Against uniQure - The complaint claims that uniQure misrepresented the approval status of the Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA timeline due to the need for additional studies [1]. - It is alleged that the defendants failed to disclose material adverse facts about uniQure's business and operations, leading to a lack of reasonable basis for their statements regarding the company's prospects [1]. Group 3: Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing to be a lead plaintiff by the specified deadline [1]. - The lead plaintiff process allows investors to represent the class in directing the litigation, with the potential for recovery not affected by the decision to serve as lead plaintiff [1].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 18, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period"). Investor Deadline: Investors who purchased uniQure securities during the Class Period may, no later than Apri ...

Core Insights - Jacob Funds released its fourth-quarter 2025 investor letter, noting a slight correction in equity markets in November despite robust economic growth throughout the year [1] - Divergent data on consumer spending and the labor market has raised doubts about future economic projections, a trend that has become common in recent years [1] - The Fund's strategy indicates that moderation in AI tech companies may benefit small companies, potentially leading to expansion in valuation multiples and favorable performance compared to peers [1] Company Focus: Prime Medicine, Inc. - Prime Medicine, Inc. (NASDAQ:PRME) is highlighted as a biotechnology company specializing in gene editing technology, with a market capitalization of $597.49 million [2] - As of February 17, 2026, Prime Medicine's stock closed at $3.31 per share, with a one-month return of -17.46% and a 12-month increase of 0.76% [2] - Jacob Funds added Prime Medicine to its portfolio, expressing confidence in its gene editing technology and the potential for significant upside if the technology proves viable [3] - The company acknowledges challenges in the gene therapy field, including safety, durability, and cost, but remains optimistic about the potential for effective cures for chronic and deadly diseases [3] - Promising efficacy and safety signals were observed in Prime Medicine's first clinical trial, indicating early positive developments in its gene editing capabilities [3]

Core Viewpoint - GenSight Biologics is strategically expanding its Regulatory Affairs & Quality department with two senior appointments following recent regulatory milestones [1] Group 1: Company Developments - The company focuses on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders [1] - The recent appointments in the Regulatory Affairs & Quality department are part of the company's efforts to enhance its regulatory capabilities [1]

LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired shares of uniQure N.V. between September 24, 2025, and October 31, 2025, due to allegations of misleading information regarding the FDA approval process for its drug candidate AMT-130 [1][2]. Group 1: Allegations and Impact - The lawsuit alleges that uniQure misled investors by failing to disclose that the design of its pivotal study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline for additional studies [2]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from its Phase I/II studies would be adequate for BLA submission, leading to a significant drop in share price from $67.69 to $34.29, a decline of over 49% [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by April 13, 2026, and participation in the case is not required to be eligible for recovery [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - A class action has been filed against uniQure N.V. for allegedly misleading investors regarding the FDA approval likelihood of its leading drug candidate, AMT-130 [1] Allegations - The complaint alleges that uniQure did not fully disclose that the design of its Pivotal Study was not fully approved by the FDA [1] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] Impact of FDA Feedback - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 would be adequate for BLA submission [1] - Following this announcement, uniQure's stock price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1] Class Action Participation - Shareholders wishing to serve as lead plaintiffs must submit their papers by April 13, 2026 [1] - Participation in the case is not required to be eligible for recovery, and representation is on a contingency fee basis [1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who acquired its securities during the specified class period, alleging misrepresentation and failure to disclose critical information regarding the company's drug development process [1][3]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [2]. Legal Allegations - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study for the drug AMT-130 and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies [3]. Stock Impact - Following the disclosure that the FDA did not agree with the use of Phase I/II data for BLA submission, uniQure's stock price plummeted over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [4].